Showing results (81-90 of 114) with videos related to

Sort By:
Pageof 12
Hemasphere|April 14, 2025
Improved post-transplant outcomes since 2000 for Ph-positive acute lymphoblastic leukemia in first remission: A study from the EBMT Acute Leukemia Working PartyAli Bazarbachi, Myriam Labopin, Iman Abou Dalle, et al.
Bone Marrow Transplantation|October 8, 2020
Salvage treatment with plerixafor in poor mobilizing allogeneic stem cell donors: results of a prospective phase II-trialKristina Hölig, Helmuth Schmidt, Gero Hütter, et al.
Bone Marrow Transplantation|July 14, 2022
Measurable residual disease (MRD) status before allogeneic hematopoietic cell transplantation impact on secondary acute myeloid leukemia outcome. A Study from the Acute Leukemia Working Party (ALWP) of the European society for Blood and Marrow Transplantation (EBMT)Enrico Maffini, Myriam Labopin, Dietrich Wilhelm Beelen, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 10, 2021
Predictive Factors for Outcome of First Allogeneic Transplant for Elderly Patients With Acute Lymphoblastic LeukemiaAbdul Hamid Bazarbachi, Myriam Labopin, Nicolaus Kröger, et al.
Bone Marrow Transplantation|December 24, 2025
The impact of DNMT3A mutation on survival of AML patients receiving allotransplant in first remission depends on the karyotype and co-occurring mutationsIman Abou Dalle, Jacques-Emmanuel Galimard, Xavier Poire, et al.
Molecular Cell|June 17, 2019
Spatial Chromosome Folding and Active Transcription Drive DNA Fragility and Formation of Oncogenic MLL TranslocationsHenrike Johanna Gothe, Britta Annika Maria Bouwman, Eduardo Gade Gusmao, et al.
American Journal of Respiratory and Critical Care Medicine|June 14, 2022
Targeting Procalcitonin Protects Vascular Barrier IntegrityLaura Brabenec, Melanie Müller, Katharina E M Hellenthal, et al.
Cancer|May 25, 2022
Additional cytogenetic features determine outcome in patients allografted for TP53 mutant acute myeloid leukemiaJustin Loke, Myriam Labopin, Charles Craddock, et al.
Bone Marrow Transplantation|December 20, 2024
Comparison of fludarabine/melphalan (FM140) with fludarabine/melphalan/BCNU (FBM110) in patients with relapsed/refractory AML undergoing allogeneic hematopoietic cell transplantation - a registry study on behalf of the EBMT Acute Leukemia Working PartyJesús Duque-Afonso, Jürgen Finke, Maud Ngoya, et al.
The Journal of Clinical Investigation|December 6, 2022
A human TRPV1 genetic variant within the channel gating domain regulates pain sensitivity in rodentsShufang He, Vanessa O Zambelli, Pritam Sinharoy, et al.
Pageof 12